NASDAQ:MEDPMedpace Stock Price, Forecast & News

Medpace's stock was trading at $83.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MEDP shares have increased by 15.2% and is now trading at $96.38. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Medpace.

Medpace is scheduled to release its next quarterly earnings announcement on Monday, July 27th 2020. View our earnings forecast for Medpace.

Medpace will be holding an earnings conference call on Monday, July 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Medpace Holdings Inc (NASDAQ:MEDP) announced its earnings results on Tuesday, April, 28th. The company reported $0.76 earnings per share for the quarter, missing the consensus estimate of $0.77 by $0.01. The company had revenue of $230.88 million for the quarter, compared to analyst estimates of $226.23 million. Medpace had a net margin of 12.37% and a return on equity of 17.18%. The company's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period last year, the business earned $0.64 EPS. View Medpace's earnings history.

5 equities research analysts have issued 12-month price targets for Medpace's stock. Their forecasts range from $75.00 to $99.00. On average, they expect Medpace's share price to reach $87.50 in the next year. This suggests that the stock has a possible downside of 9.2%. View analysts' price targets for Medpace.

Media headlines about MEDP stock have been trending very negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medpace earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Medpace.

Some companies that are related to Medpace include EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA) and Auxly Cannabis Group (CBWTF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Baidu (BIDU), Alibaba Group (BABA), Square (SQ), JD.Com (JD), Trade Desk (TTD), Adobe (ADBE), Alteryx (AYX) and Cisco Systems (CSCO).

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by a variety of institutional and retail investors. Top institutional investors include MERIAN GLOBAL INVESTORS UK Ltd (0.35%), Envestnet Asset Management Inc. (0.10%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View institutional ownership trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, and Louisiana State Employees Retirement System. Company insiders that have sold Medpace company stock in the last year include Jesse J Geiger, Medpace Investors, Llc, and Stephen P Ewald. View insider buying and selling activity for Medpace.

MEDP stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $96.38.

Medpace has a market capitalization of $3.41 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe.

The official website for Medpace is www.medpace.com.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]